133 related articles for article (PubMed ID: 3004156)
1. Beneficial effects of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate, a specific PAF antagonist, in endotoxin and anaphylactic shock.
Terashita Z; Imura Y; Nishikawa K; Sumida S
Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():715-7. PubMed ID: 3004156
[No Abstract] [Full Text] [Related]
2. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
4. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
[TBL] [Abstract][Full Text] [Related]
6. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat.
Toth PD; Mikulaschek AW
Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423
[TBL] [Abstract][Full Text] [Related]
7. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.
Doebber TW; Wu MS; Biftu T
J Immunol; 1986 Jun; 136(12):4659-68. PubMed ID: 3011900
[TBL] [Abstract][Full Text] [Related]
8. The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure.
Anderson BO; Bensard DD; Harken AH
Surg Gynecol Obstet; 1991 May; 172(5):415-24. PubMed ID: 1851337
[TBL] [Abstract][Full Text] [Related]
9. Effect of SR 27417 on the binding of [3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes.
Herbert JM; Laplace MC; Cailleau C; Maffrand JP
J Lipid Mediat; 1993 May; 7(1):57-78. PubMed ID: 8395255
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological modulation of PAF: a therapeutic approach to endotoxin shock.
Sánchez Crespo M; Fernández-Gallardo S
J Lipid Mediat; 1991; 4(2):127-43. PubMed ID: 1659463
[No Abstract] [Full Text] [Related]
11. [Platelet-activating factor (PAF) receptor-related pathophysiology].
Ishii S; Shimizu T
Tanpakushitsu Kakusan Koso; 1999 Jun; 44(8 Suppl):1068-74. PubMed ID: 10396985
[No Abstract] [Full Text] [Related]
12. Pharmacological profile of TCV-309--a potent PAF antagonist.
Terashita Z; Takatani M; Nishikawa K
J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598
[TBL] [Abstract][Full Text] [Related]
13. Recent development of platelet-activating factor antagonists.
Shen TY; Hussaini I; Hwang SB; Chang MN
Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():359-62. PubMed ID: 2546389
[No Abstract] [Full Text] [Related]
14. Interrelationships among platelet-activating factor binding and metabolism and induction of platelet activation.
Valone FH
Prog Clin Biol Res; 1988; 283():319-40. PubMed ID: 2850575
[No Abstract] [Full Text] [Related]
15. Characterization of platelet-activating factor (PAF) receptor in the rat brain.
Bito H; Kudo Y; Shimizu T
J Lipid Mediat; 1993; 6(1-3):169-74. PubMed ID: 8395241
[TBL] [Abstract][Full Text] [Related]
16. Platelet-activating factor binding to human platelet membranes.
Valone FH; Ruis NM
Biotechnol Appl Biochem; 1986 Oct; 8(5):465-70. PubMed ID: 3021183
[TBL] [Abstract][Full Text] [Related]
17. Activation of guinea pig peritoneal macrophages by platelet activating factor (PAF) and its agonists.
Hayashi H; Kudo I; Inoue K; Onozaki K; Tsushima S; Nomura H; Nojima S
J Biochem; 1985 Jun; 97(6):1737-45. PubMed ID: 2993272
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
Ring PC; Seldon PM; Barnes PJ; Giembycz MA
Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
[TBL] [Abstract][Full Text] [Related]
19. Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist.
Handley DA; Van Valen RG; Melden MK; Flury S; Lee ML; Saunders RN
Immunopharmacology; 1986 Aug; 12(1):11-6. PubMed ID: 3019921
[TBL] [Abstract][Full Text] [Related]
20. Membrane and intracellular platelet-activating factor receptor expression in leukemic blasts of patients with acute myeloid and lymphoid leukemia.
Donnard M; Guglielmi L; Turlure P; Piguet C; Couraud MJ; Bordessoule D; Denizot Y
Stem Cells; 2002; 20(5):394-401. PubMed ID: 12351810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
